Published in Vaccine Weekly, December 27th, 2006
This patent covers purified adenoviral compositions or preparations without limitation to the type of adenovirus, the use or application of the adenovirus, and without limitation as to how the adenovirus is produced. This patent complements two previously issued U.S. patents in Introgen's intellectual property portfolio directed to the production of adenoviral vectors.
"This patent adds considerably to Introgen's extensive adenovirus intellectual property portfolio,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly